港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

拨康视云－Ｂ

5.350

+0.1703.28%

成交量：34.30万

成交额：182.78万

市值：44.88亿

市盈率：-3.29

高：5.390

开：5.200

低：5.200

收：5.180

52周最高：9.740

52周最低：4.930

股本：8.39亿

香港流通股本：8.39亿

量比：0.78

换手率：0.04%

股息：- -

股息率：- -

每股收益(LYR):-1.628

净资产收益率：--

总资产收益率：-44.38%

市净率：-1.63

市盈率(LYR):-3.29

市销率: 57.47

数据加载中...

总览公司新闻公告

异动解读 | 拨康视云-B盘中大跌6.45%，上市后持续下跌，较发行价已跌超42%

异动解读 | 拨康视云-B盘中大跌6.45%，上市次日较招股价已跌超42%

70后实控人接盘前妻公司冲击IPO，二婚娶90后

正大天晴重组人凝血因子VIIa获批上市；拨康视云上市首日破发

手握2款3期新药，眼科明星Biotech港股上市

动脉新医药

拨康视云正式上市百惠担任联席账簿管理人及联席牵头经办人

中宏网官微

新股首日 | 拨康视云-B跌超16%，公司为临床阶段眼科生物科技公司

异动解读 | 拨康视云-B首日挂牌大跌7.43%，IPO超额认购热情难挽股价下跌

异动解读 | 拨康视云-B上市首日盘中大跌7.43%，较招股价跌超13%

港股公告掘金 | 小鹏汽车6月智能电动汽车交付量同比增长224% 拨康视云明日上市

拨康视云-B(02592)公开发售获78.78倍认购全球发售净筹约5.22亿港元

老虎暗盘｜拨康视云涨近9%，中签一手赚超450港元，市值92.28亿港元

老虎资讯综合

拨康视云四战港交所：三年亏损超20亿元，创始人千万年薪碾压同行

拨康视云四战港交所：三年亏损超20亿元，创始人千万年薪碾压同行

【港股IPO动态：今日周六福、圣贝拉、颖通控股上市】今日周六福(6168.HK)、圣贝拉(2508.HK)、颖通控股(6883.HK)上市，BOSS直聘-W(2076.HK)、安井食品(2648.HK)、拨康视云-B (2592.HK)申购。

音频 | 格隆汇6.25盘前要点—港A美股你需要关注的大事都在这

拨康视云引入基石投资者助力眼科创新药研发

拨康视云-B(02592)今起招股引入富策控股及Reynold Lemkins作为基石

【拨康视云-B(02592.HK)今起招股引入富策控股及Reynold Lemkins作为基石】智通财经APP讯，拨康

【新股IPO】拨康视云-B(02592)今日起招股入场费5,100.94港元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02592/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02592","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","market":"HK","secType":"STK","nameCN":"拨康视云－Ｂ","latestPrice":5.35,"timestamp":1756179366830,"preClose":5.18,"halted":0,"volume":343000,"delay":0,"floatShares":838892874,"shares":838892874,"eps":-1.6284527258670372,"marketStatus":"交易中","change":0.17,"latestTime":"08-26 11:36:25","open":5.2,"high":5.39,"low":5.2,"amount":1827820,"amplitude":0.03668,"askPrice":5.35,"askSize":10500,"bidPrice":5.34,"bidSize":4000,"shortable":0,"etf":0,"ttmEps":-1.6284527258670372,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1756180800000},"marketStatusCode":2,"adr":0,"listingDate":1751472000000,"exchange":"SEHK","adjPreClose":5.18,"openAndCloseTimeList":[[1756171800000,1756180800000],[1756184400000,1756195200000]],"volumeRatio":0.775535,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","floatShares":838892874,"roa":"-44.38%","roe":"--","lyrEps":-1.628478,"volumeRatio":0.775535,"shares":838892874,"dividePrice":0,"high":5.39,"amplitude":0.03668,"preClose":5.18,"low":5.2,"week52Low":4.93,"pbRate":"-1.63","psRate":"57.47","week52High":9.74,"institutionHeld":0,"latestPrice":5.35,"committee":-0.448276,"eps":-1.6284781607041054,"divideRate":0,"volume":343000,"delay":0,"ttmEps":-1.6284781607041054,"open":5.2,"prevYearClose":10.1,"prevWeekClose":5.11,"prevMonthClose":5.35,"prevQuarterClose":10.1,"fiveDayClose":5.54,"twentyDayClose":5.6,"sixtyDayClose":10.1,"earningDate":1756396800000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02592\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02592\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02592\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02592\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02592","date":"2025-08-25","current":-5.611715,"percent":0.72973,"low":-6.683808,"twenty":-6.312981,"median":-6.000684,"eighty":-5.556503,"high":-5.433303,"avg":-5.949854,"sd":0.371248,"marketCap":4345465087},"quantilePoints":[{"date":"2025-07-04","current":-6.317277,"twenty":-6.610502,"median":-6.500542,"eighty":-6.390583,"marketCap":4915912241},{"date":"2025-07-11","current":-6.166376,"twenty":-6.470405,"median":-6.317277,"eighty":-6.263403,"marketCap":4798467239},{"date":"2025-07-18","current":-6.350904,"twenty":-6.498689,"median":-6.350281,"eighty":-6.263403,"marketCap":4941079027},{"date":"2025-07-25","current":-6.080141,"twenty":-6.48004,"median":-6.306537,"eighty":-6.134066,"marketCap":4731355809},{"date":"2025-08-01","current":-5.497985,"twenty":-6.418895,"median":-6.177156,"eighty":-6.011186,"marketCap":4278353657},{"date":"2025-08-08","current":-5.49809,"twenty":-6.350655,"median":-6.13405,"eighty":-5.65539,"marketCap":4278353657},{"date":"2025-08-15","current":-5.725306,"twenty":-6.343182,"median":-6.058573,"eighty":-5.554248,"marketCap":4446132232},{"date":"2025-08-22","current":-5.53457,"twenty":-6.315129,"median":-6.004685,"eighty":-5.554248,"marketCap":4286742586},{"date":"2025-08-25","current":-5.611715,"twenty":-6.312981,"median":-6.000684,"eighty":-5.556503,"marketCap":4345465087}],"updateTime":1756179385084},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02592\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1111120890","title":"异动解读 | 拨康视云-B盘中大跌6.45%，上市后持续下跌，较发行价已跌超42%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111120890","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111120890?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 15:02","pubTimestamp":1751612554,"startTime":"0","endTime":"0","summary":"港股市场上，拨康视云-B今日盘中大跌6.45%，延续了上市以来的跌势。截至盘中，该股报5.81港元，成交额达3729.14万港元。值得注意的是，这已是该股上市后的第二个交易日，而其股价较招股价已累计下跌超过42%，引发市场关注。其中，公司拥有两款核心产品CBT-001和CBT-009，均为自主开发。尽管拨康视云-B在眼科药物研发领域展现出潜力，但其上市后的持续下跌反映出投资者对该股的谨慎态度。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"417db6c0ab0fdec18dfd33a47098c1b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02592"],"gpt_icon":1},{"id":"1109428087","title":"异动解读 | 拨康视云-B盘中大跌6.45%，上市次日较招股价已跌超42%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109428087","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109428087?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 15:02","pubTimestamp":1751612543,"startTime":"0","endTime":"0","summary":"拨康视云-B今日盘中大跌6.45%，延续上市首日的跌势。截至下午2点55分，该股报5.81港元，成交额达3729.14万港元。值得注意的是，与招股价相比，拨康视云-B的股价已累计下跌超过42%，引发市场关注。根据公司招股书显示，拨康视云-B拥有两款核心产品CBT-001和CBT-009。其中，CBT-001用于治疗翼状胬肉，公司已分别于2022年6月和2023年9月在美国和中国启动第3期多地区临床试验。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"417db6c0ab0fdec18dfd33a47098c1b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02592"],"gpt_icon":1},{"id":"2548388797","title":"70后实控人接盘前妻公司冲击IPO，二婚娶90后","url":"https://stock-news.laohu8.com/highlight/detail?id=2548388797","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548388797?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 20:01","pubTimestamp":1751544060,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　近日，武汉里得电力科技股份有限公司 北交所IPO申请获受理，保荐机构为开源证券股份有限公司。　　本次IPO前，王颂锋担任公司董事长兼总经理，合计控制公司64%的表决权股份，是公司的控股股东和实际控制人。其开盘平开，总市值80亿港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hyyj/2025-07-03/doc-infefhcf3766512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02592","SPD"],"gpt_icon":1},{"id":"2548389651","title":"正大天晴重组人凝血因子VIIa获批上市；拨康视云上市首日破发","url":"https://stock-news.laohu8.com/highlight/detail?id=2548389651","media":"氨基观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548389651?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 19:09","pubTimestamp":1751540990,"startTime":"0","endTime":"0","summary":"正大天晴又有新收获。7月3日，创新药企拨康视云港股上市。二级市场方面，公司表现不佳，上市首日破发，大跌38.61%。9）正大天晴重组人凝血因子VIIa获批上市7月3日，据NMPA官网，正大天晴的注射用重组人凝血因子VIIa已获批上市，适应症为抑制物阳性先天性血友病A或B患者以及某些特定类型罕见出血性疾病患者群体出血的治疗和外科手术或有创操作出血的防治。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703191301a72ca04f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703191301a72ca04f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592"],"gpt_icon":1},{"id":"2548896683","title":"手握2款3期新药，眼科明星Biotech港股上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2548896683","media":"动脉新医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548896683?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 19:05","pubTimestamp":1751540741,"startTime":"0","endTime":"0","summary":"7月3日，“眼科创新药新锐”Cloudbreak Pharma Inc.拨康视云在港交所正式上市。其全球治疗药物市场规模预计将于2027年达到2.73亿美元、2032年达到25.29亿美元，复合年增长率为56.0%。因此，CBT-001有望成为治疗翼状胬肉的全球首创药物，享有先发优势。弗若斯特沙利文报告显示，全球治疗青少年近视药物的市场规模由2018年的7230万美元增加至2022年的8400万美元，复合年增长率为3.8%。2022年，全球睑板腺功能异常相关的干眼症患者人数将达到9.232亿人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703190942a4cd3dcc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703190942a4cd3dcc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSTECH","07226","02592","HSCEI"],"gpt_icon":1},{"id":"2548708798","title":"拨康视云正式上市 百惠担任联席账簿管理人及联席牵头经办人","url":"https://stock-news.laohu8.com/highlight/detail?id=2548708798","media":"中宏网官微","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548708798?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 16:27","pubTimestamp":1751531220,"startTime":"0","endTime":"0","summary":"，正式登陆香港联交所主板，每股定价为10.10港元，录得近78倍超额认购，百惠金控团队担任联席账簿管理人及联席牵头经办人。　　作为本次 IPO 项目的联席账簿管理人及联席牵头经办人，百惠金控团队充分调动自身广泛的市场资源，为拨康视云提供全周期上市解决方案。同时，旗下的百惠资本持有第六类牌照，并且拥有保荐人资格。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-07-03/doc-infeevpi3404944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02592"],"gpt_icon":1},{"id":"2548502842","title":"新股首日 | 拨康视云-B跌超16%，公司为临床阶段眼科生物科技公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2548502842","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548502842?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 09:38","pubTimestamp":1751506715,"startTime":"0","endTime":"0","summary":"7月3日，拨康视云-B首日盘初跌超16%，成交额8232万港元。公开资料显示，拨康视云是一间临床阶段眼科生物科技公司，致力于开发各种疗法。集团已经建立一个由候选药物组成的创新管线，覆盖眼睛前部和后部的主要疾病，其中有四款处于临床阶段的候选药物及四款处于临床前阶段的候选药物，管线中的所有候选药物均为自主研发。核心产品CBT-001适用于治疗翼状胬肉，集团分别于2022年6月及2023年9月在美国及中国启动第3期多地区临床试验。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"417db6c0ab0fdec18dfd33a47098c1b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1313367.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592"],"gpt_icon":0},{"id":"1191258223","title":"异动解读 | 拨康视云-B首日挂牌大跌7.43%，IPO超额认购热情难挽股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1191258223","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191258223?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 09:32","pubTimestamp":1751506361,"startTime":"0","endTime":"0","summary":"临床阶段眼科生物科技公司拨康视云-B今日在港交所挂牌上市，盘中大跌7.43%，引发市场关注。拨康视云-B此前以每股10.1港元的价格完成全球发售，共发行6058.2万股股份，募集资金净额约5.22亿港元。公司香港公开发售部分获得78.78倍超额认购，显示出投资者的热烈兴趣。然而，这种热情似乎并未延续到二级市场。尽管IPO认购火热，但拨康视云-B上市首日表现不佳可能与多重因素有关。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"417db6c0ab0fdec18dfd33a47098c1b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02592"],"gpt_icon":0},{"id":"1187279368","title":"异动解读 | 拨康视云-B上市首日盘中大跌7.43%，较招股价跌超13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187279368","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187279368?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 09:32","pubTimestamp":1751506350,"startTime":"0","endTime":"0","summary":"拨康视云-B今日在港交所主板挂牌上市，盘中大跌7.43%，股价跌至9.35港元，较10.1港元的招股价下跌超过13%，引发市场关注。拨康视云-B是一家临床阶段眼科生物科技公司，致力于开发新型及差异化疗法。然而，该股今日开盘即表现疲软，开盘价为9.5港元，较招股价低5.94%。分析人士指出，尽管公司IPO获得较高认购倍数，但上市首日股价表现不佳，可能反映了投资者对生物科技公司长期盈利能力的担忧，以及当前市场对新股的谨慎态度。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"417db6c0ab0fdec18dfd33a47098c1b2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02592"],"gpt_icon":0},{"id":"2548381566","title":"港股公告掘金 | 小鹏汽车6月智能电动汽车交付量同比增长224% 拨康视云明日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2548381566","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548381566?lang=zh_cn&edition=fundamental","pubTime":"2025-07-02 22:58","pubTimestamp":1751468287,"startTime":"0","endTime":"0","summary":"【重大事项】拨康视云-B(02592)公开发售获78.78倍认购 全球发售净筹约5.22亿港元首钢朗泽(02553)因民事诉讼将延迟全球发售及上市德林控股(01709)拟携手Asseto在亚洲市场共同探索并开发RWA的代币化解决方案万国数据-SW(09698)：C-REIT的首次公开发售(IPO)的最终发售价为每份额3.00元宜明昂科-B(01541)：IMM2510/AXN-2510获美国FDA","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c1a5d46f67449d510f0b2e6d4ffc20b7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1313300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","XPEV","02603","BK4614","BK1108","01045","EVS.SI","HSCEI","07226","LU0593848301.USD","YANG","BK1575","BK4099","09868","BK1610","BK4526","BK1587","HSTECH","BK4505","BK4551","BK1119","BK1539","02592","BK4555","BK1137"],"gpt_icon":0},{"id":"2548852894","title":"拨康视云-B(02592)公开发售获78.78倍认购 全球发售净筹约5.22亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548852894","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548852894?lang=zh_cn&edition=fundamental","pubTime":"2025-07-02 20:07","pubTimestamp":1751458071,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B(02592)公布配发结果，公司全球发售6058.2万股股份，香港公开发售占20%，国际发售占80%。最终发售价为每股10.1港元，全球发售净筹约5.22亿港元。每手500股，预期股份将于 2025年7月3日(星期四)上午九时正(香港时间)在联交所开始买卖。其中，香港公开发售获78.78倍认购，国际发售获0.89倍认购。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1313222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592"],"gpt_icon":0},{"id":"1142745540","title":"老虎暗盘｜拨康视云涨近9%，中签一手赚超450港元，市值92.28亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1142745540","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142745540?lang=zh_cn&edition=fundamental","pubTime":"2025-07-02 16:33","pubTimestamp":1751445224,"startTime":"0","endTime":"0","summary":"周三，拨康视云开启暗盘涨近9%，中签一手赚超450港元，市值92.28亿港元公司介绍：集团是一间临床阶段眼科生物科技公司，致力于开发各种疗法。集团已订立基石投资协议，据此，在若干条件规限下，基石投资者已同意按发售价认购以总额2280万美元可认购的发售股份数目。按每股发售股份发售价10.10港元计算，估计集团将自全球发售收取所得款项净额约5.222亿港元。","market":"us","thumbnail":"https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6b69e234a63c2c0a69ccede7b0faaa18"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"105923918965a0539d0eff1a540dbfb5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"gpt_icon":0},{"id":"2548005855","title":"拨康视云四战港交所：三年亏损超20亿元，创始人千万年薪碾压同行","url":"https://stock-news.laohu8.com/highlight/detail?id=2548005855","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548005855?lang=zh_cn&edition=fundamental","pubTime":"2025-07-01 19:11","pubTimestamp":1751368300,"startTime":"0","endTime":"0","summary":"此前，拨康视云先后于2023年11月、2024年5月、2024年12月三次向港交所递交上市申请，均以失败告终。根据许可协议，拨康视云获得了1000万美元的首付款，预计还能获得临床开发及监管里程碑付款总计不超过9100万美元，并有权根据销售额收取分级专利权费付款。据招股书，倪劲松及其配偶通过间接持股及家族信托，合计持有拨康视云股份约22.18%，其中倪劲松持有约20.86%，其配偶持有约1.32%。拨康视云核心管理层的现金薪酬水平显著高于行业头部企业掌舵者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1751104966030417205","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["02592"],"gpt_icon":1},{"id":"2546724212","title":"拨康视云四战港交所：三年亏损超20亿元，创始人千万年薪碾压同行","url":"https://stock-news.laohu8.com/highlight/detail?id=2546724212","media":"子弹财观","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546724212?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 21:00","pubTimestamp":1751029220,"startTime":"0","endTime":"0","summary":"此前，拨康视云先后于2023年11月、2024年5月、2024年12月三次向港交所递交上市申请，均以失败告终。根据许可协议，拨康视云获得了1000万美元的首付款，预计还能获得临床开发及监管里程碑付款总计不超过9100万美元，并有权根据销售额收取分级专利权费付款。据招股书，倪劲松及其配偶通过间接持股及家族信托，合计持有拨康视云股份约22.18%，其中倪劲松持有约20.86%，其配偶持有约1.32%。拨康视云核心管理层的现金薪酬水平显著高于行业头部企业掌舵者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627210300a4c14da4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627210300a4c14da4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592"],"gpt_icon":1},{"id":"2546214982","title":"【港股IPO动态：今日周六福、圣贝拉、颖通控股上市】今日周六福(6168.HK)、圣贝拉(2508.HK)、颖通控股(6883.HK)上市，BOSS直聘-W(2076.HK)、安井食品(2648.HK)、拨康视云-B (2592.HK)申购。","url":"https://stock-news.laohu8.com/highlight/detail?id=2546214982","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546214982?lang=zh_cn&edition=fundamental","pubTime":"2025-06-26 06:35","pubTimestamp":1750890915,"startTime":"0","endTime":"0","summary":"今日周六福(6168.HK)、圣贝拉(2508.HK)、颖通控股(6883.HK)上市，BOSS直聘-W(2076.HK)、安井食品(2648.HK)、拨康视云-B (2592.HK)申购。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9835176c868bcdb544d7d548fe3d02fe","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/26063551311402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1148","BK4526","LU2039709279.SGD","BK4539","BK4509","LU1997245177.USD","BK4585","LU0359202008.SGD","BK4503","BZ","BK4505","02076","02592","06883","LU0359201612.USD","02648","YANG","02508","BK4535","BK4077","BK0201","BK0238","LU1688375341.USD","BK1095","BK4551","603345","LU1023057109.AUD","LU1997245094.SGD","BK4614","BK4588","HSTECH","IE00B29SXG58.USD","BK4563","06168"],"gpt_icon":0},{"id":"2546519142","title":"音频 | 格隆汇6.25盘前要点—港A美股你需要关注的大事都在这","url":"https://stock-news.laohu8.com/highlight/detail?id=2546519142","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546519142?lang=zh_cn&edition=fundamental","pubTime":"2025-06-25 07:38","pubTimestamp":1750808328,"startTime":"0","endTime":"0","summary":"以伊停火生效，美股三大指数均涨超1%，中概指数涨3.31%，美油期货大跌6%；鲍威尔称或可提前降息；欧盟拟采取更多反制措施以对美施压；提及中长期资金入市、提高居民财产性收入，央行等六部门发文；柠檬价格暴涨300%...","market":"us","thumbnail":"https://img7.gelonghui.com/column/2/109.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/109.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/2380950","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1502","BK1604","02592","BK1587","BK1541","BK1151","02618"],"gpt_icon":0},{"id":"2545470372","title":"拨康视云引入基石投资者 助力眼科创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2545470372","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545470372?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 14:35","pubTimestamp":1750746902,"startTime":"0","endTime":"0","summary":"眼科创新药研发商拨康视云近日宣布，在本次发行中成功引入两名基石投资者，累计认购金额达2280万美元（约1.79亿港元）。其中，知名天使投资人龚虹嘉全资持有的富策控股认购2000万美元，瑞凯集团认购280万美元。拨康视云专注于小分子多激酶抑制剂和抗体-小分子协作偶联技术平台的开发，覆盖眼表、青光眼及眼底疾病领域。此次融资将加速其创新药物的研发进程，为眼科疾病治疗提供更多解决方案。基石投资者的加入，进一步彰显市场对其技术实力和发展前景的认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624143918978c634f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624143918978c634f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02592","06978","BK1574"],"gpt_icon":0},{"id":"2545653424","title":"拨康视云-B(02592)今起招股 引入富策控股及Reynold Lemkins作为基石","url":"https://stock-news.laohu8.com/highlight/detail?id=2545653424","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545653424?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 09:14","pubTimestamp":1750727668,"startTime":"0","endTime":"0","summary":"集团拥有两款核心产品，均为自主开发。核心产品CBT-001适用于治疗翼状胬肉，集团分别于2022年6月及2023年9月在美国及中国启动第3期多地区临床试验。自成立以来，公司尚未获利，并且每年均取得经营亏损。于截至2022年、2023年及2024年12月31日止年度，我们的经营亏损分别为2300万美元、3720万美元及3660万美元。按发售价10.10港元计算，基石投资者将予认购的发售股份总数将为1772万股发售股份。基石投资者包括富策控股有限公司及The Reynold Lemkins Group  Limited。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1308741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592"],"gpt_icon":0},{"id":"2545424632","title":"【拨康视云-B(02592.HK)今起招股 引入富策控股及Reynold Lemkins作为基石】智通财经APP讯，拨康","url":"https://stock-news.laohu8.com/highlight/detail?id=2545424632","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545424632?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 09:14","pubTimestamp":1750727668,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02592"],"gpt_icon":0},{"id":"2545397421","title":"【新股IPO】拨康视云-B(02592)今日起招股 入场费5,100.94港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545397421","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545397421?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 08:42","pubTimestamp":1750725757,"startTime":"0","endTime":"0","summary":"金吾财讯 | 拨康视云-B(02592)今日起招股，拟发行6058.2万股，其中90%)为国际发售，10%)为香港发售。每股招股价为10.1港元，每手500股，入场费5,100.94港元，建银国际、华泰国际为联席保荐人。股份预期将于7月3日挂牌上市。此次集资净额预期为5.22亿港元，公司拟将其中约62.4%将用于拨付核心产品CBT-001的持续临床研发活动，以及注册备案及获批后研究所需资金；约27.6%将用于拨付持续临床研发活动，以及核心产品CBT-009的注册备案的所需资金；约5.5%将用于拨付生产设施及商业化活动所需资金；及约4.5%将用作营运资金及其他一般企业用途。","market":"sg","thumbnail":"https://static.szfiu.com/news/20220324/Mjg2N2JhODhiZjBhODVmMjEwMzAwNTY4MTI5NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/Mjg2N2JhODhiZjBhODVmMjEwMzAwNTY4MTI5NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1960968","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":66,"code":"91000000","status":"200"}]}}